SABCS: Novartis touts Kisqali’s 5-year breast cancer survival, advantage over Pfizer’s Ibrance – FiercePharma
Posted: December 10, 2020 at 4:58 pm
Novartis already knew that adding Kisqali to endocrine therapy can help premenopausal patients with HR-positive, HER2-negative advanced breast cancer live longer. Now, it knows exactly how long.
Kisqali plus endocrine therapy helped pre- and perimenopausal women with HR+/HER2- disease live a median 58.7 months, according to phase 3 data presented at the San Antonio Breast Cancer Symposium's (SABCS') virtual annual meeting. Thats compared with 48 months forendocrine therapy alone, translating to a 24% reduction in the risk of death for the Kisqali regimen.
Deploy Configurable, Fit-for-Purpose ePRO Solutions, Fast.
Clinical Inks enhanced Lunexis ePRO+ module streamlines processes through a flexible, unified platform that allows patients and sites a high degree of optionality.
Jeff Legos, Ph.D., Novartis head of oncology drug development, called Kisqalis new survival showing very impressive given that these patients historically survived for around three years after treatment. Patients in the control arm of the Monaleesa-7 trial appeared to live longer because some went on to receive Kisqali afteran initial survival readout, which showed a 29% reduction in the risk of death.
The Kisqali regimen also extended the time period before patients need follow-up chemotherapy by about 31%. Patients on the Kisqali combo lived a median 50.9 months before their first post-treatment chemo, while the time was 36.8 months for endocrine therapy alone.
The survival benefit was similar in a subgroup of patients who took a nonsteroidal aromatase inhibitor (NSAI) as part of their endocrine therapy. The death risk reduction in those patients was 20%, as the Kisqali group also lived a median 58.7 months, versus 47.7 months for the control arm.
RELATED:ASCO: Novartis' Kisqali posts first-in-class survival win in younger women
Thats the most relevant data for Kisqali in this patient population,given that its only approved by the FDA in combination with an NSAI. The Monaleesa-7 study also tested tamoxifen as an endocrine option, but, in those patients, researchers identified ahigher-than-expected increase in an abnormal heart rhythm called QT prolongation.
Novartis has now reported statistically significant life extension benefits for Kisqali in premenopausal women in the Monaleesa-7 trial and in postmenopausal women in the Monaleesa-3 study.The Monaleesa-2 program testing Kisqali in combination with the endocrine therapy letrozole in previously untreated patients is expected to have overall survival data in the second half of 2021.
The current Monaleesa-7 study was carried out in patients who hadnt been previously treated witha CDK4/6 inhibitor or endocrine therapy, but it did allowprevious treatment with chemotherapy.
Biomarker victory over Ibrance
In a cherry on top of Kisqalis 2020 SABCS data cake, Novartis unveiled a pooled analysis of the three trials showing the CDK4/6 inhibitor reduced the risk of disease progression or death in three of the four main subtypes of breast cancer.
In patients with the more traditional Luminal A and Luminal B subtypes, where Legos said patients have done reasonably OK with solo endocrine therapy, adding Kisqali significantly slashed the risk of disease progression or death by 37% and 48%, respectively, across the three trials.
The best news for Kisqali, though, according to Legos, came fromthe HER2-enriched subtype, which makes up about 15% of the HR+/HER2- breast cancer population. This subgroup traditionally had not done very well on endocrine therapy alone and hence it can be sort of deemed as a poor prognostic factor, Legos explained.
But in this group, the Kisqali-endocrine pairing cut the risk of disease progression or death by 61%.
RELATED:ESMO: Lilly's Verzenio pressures Pfizer with practice-changing win in early breast cancer
The showing in this subtype is important because its the first time a CDK4/6 inhibitor combo topped endocrine therapy alonein these women, Legos said. Three years ago at the SABCS event, a retrospective analysis of the Paloma-2 trial found Pfizers market-leading CDK4/6 inhibitor, Ibrance, didnt benefit the HER2-enriched subtype, he pointed out.
I think this just addsto the growing body of evidence that these mixed results that were seeing in both the metastatic setting, as well as in the adjuvant setting, may suggest that not all of the CDK4/6 inhibitors are equal, Legos said in an interview ahead of the data presentation.
Indeed, Ibrance has repeatedly failed in several HR+/HER2- breast cancer trials. The most famous is the Paloma-3 trial, which showed adding Ibrance to endocrine therapy in metastatic patients didnt significantly beat endocrine therapy at extending patients lives.
RELATED:Pfizer's Ibrance kisses early breast cancer hopes goodbye with 2nd study failure
And, in the postsurgery setting known as adjuvant treatment, Ibrance recently failed to lengthen the time early breast cancer patients could live without invasive disease returning. It didnt deliver a benefit in a wider patient group or in a high-risk subgroup.
Meanwhile, updated data from the phase 3 monarchE trial presented at this years SABCS showed the adjuvant pairing of Eli Lillys rival CDK4/6 inhibitor Verzenio and endocrine therapy reduced the risk of invasive disease after surgery by 28.7% in high-risk patients with an extended follow-up of 19 months.
CDK4 versus CDK6
Novartis has been attributing Kisqalis better efficacyas compared to Ibrancesto its drugs higher inhibition of CDK4 over CDK6. While CDK4 is more widely expressed in breast cancer cells, CDK6 is found more in the bone marrow; plus, CDK4 plays a greater role in cell proliferation and growth, Legos explained. Verzenio also inhibits CDK4 to a higher degree.
Kisqali isnt omnipotent, though. The Novartis drug didnt show a tumor progression improvement in the basal-like subtype. Legos said this represents a small group of patients whose tumors resemble triple-negative breast cancer. These patients constitute an average 3% of participants across the three Monaleesa trials, which Legos said is reflective of the real-world makeup.
Novartis is running a separate trial called Natalee, hoping to show that Kisqali on top of endocrine therapy works as an adjuvant treatment for both intermediate and high-risk patients. Data from that trial areexpected in 2022.
- The sun shines for Wirsol Energy: guidance on the circumstances in which waiver can be given in a commercial contract - Lexology - April 17th, 2021
- The age of information Aerospace Manufacturing - Aerospace Manufacturing - April 17th, 2021
- JK Group Unveils Sustainability Initiatives - Covering the Printing Inks, Coatings and Allied Industries - Ink World - Ink World Magazine - April 17th, 2021
- Market Assessment of Pyrroloquinoline Quinone Industry: Growth Drivers by Top Players like Haotian Pharm, Doctor's Best, Health Thru Nutrition, Life... - April 17th, 2021
- Northrop Grumman and Intelsat make history with Docking of 2nd Mission Extension Vehicle - Sea News - April 17th, 2021
- PEF can become the 'standard in the food and drink industry', says plastics producer - FoodNavigator.com - April 17th, 2021
- Belfast Harbour invests 2.5m in refurbishment of Terminal 1 - Belfast Newsletter - April 17th, 2021
- Springfield National Weather Service radar scheduled outage coming, will last about a week - KOLR - OzarksFirst.com - February 25th, 2021
- Global Military Aircraft Modernization and Upgrade and Retrofit Markets to 2024: Incorporation of CNS Systems in aircraft and Emergence of SVAB -... - February 25th, 2021
- Real-Time Communication with Dreaming Person Possible, Says Study | The Weather Channel - Articles from The Weather Channel | weather.com - The... - February 25th, 2021
- Canned Soups Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Type, Category, Processing, and Distribution Channel - GlobeNewswire - February 25th, 2021
- Star Royalties Closes Second US$6 Million Installment of US$18 Million Stream Financing for the Restart of the Copperstone Gold Mine - Junior Mining... - February 25th, 2021
- Norwegian Army Adding 20 CV90s to Its Fleet - Business Wire - February 25th, 2021
- Calico Purring Right Along With Life Extension Research - Nanalyze - February 1st, 2021
- Get healthy in Feb. with AgriLife - Pleasanton Express - February 1st, 2021
- Wellness Supplements Market Statistics 2021- Industry Insights and COVID-19 impact analysis with Future Opportunities 2027 | Life Extension, OPTAVIA,... - February 1st, 2021
- Great Panther Files NI 43-101 Technical Report for the Tucano Gold Mine and Provides Update on Exploration Strategy and Programs for 2021 - PRNewswire - February 1st, 2021
- Sweden Looks to the Past to Prepare for Its Defense Future - Defense & Security Monitor - January 29th, 2021
- Yamana Gold Provides 2021-2023 Guidance and Ten-Year Overview - GlobeNewswire - January 29th, 2021
- Here are the challenges involved in building the future US Navy - DefenseNews.com - January 25th, 2021
- Divine Flavor adopts StePac' modified atmosphere standing pouches for extending produce shelf life in the retail sector - PRNewswire - January 25th, 2021
- miRagen Therapeutics Announces Company Name Change to Viridian Therapeutics and New Executive Appointments, Including Expansion of Leadership Team -... - January 25th, 2021
- Capstone Advances Two Operational Growth Projects to Sustain 200 Mlbs Copper Production Starting in 2022 - Business Wire - January 25th, 2021
- 2 More Drugs Recommended To Treat Covid In UK, But Not In US - Kaiser Health News - January 12th, 2021
- The Venture Bros: 10 Biggest Twists In The Series | CBR - CBR - Comic Book Resources - January 12th, 2021
- DNA-editing method shows promise to treat mouse model of progeria - National Human Genome Research Institute - January 9th, 2021
- Digital twins and design innovation - Engineer Live - January 9th, 2021
- Harpoon Therapeutics : Clin Cancer Res 2021; OnlineFirst version Jan 6, 2021 - Marketscreener.com - January 9th, 2021
- Massive Science Year in Review: 2020 edition - Massive Science - January 9th, 2021
- Panthera began dosing volunteers in AstraZeneca's phase III of its long-acting antibody combination AZD7442 for the prevention of COVID-19 at its... - January 9th, 2021
- National Guard troops to take back seat as Trump addresses supporters rallying to his call to overturn the election - Washington Examiner - January 9th, 2021
- Several AF fighter jets, combat helicopters to be overhauled to boost air power - Daily Mirror - January 9th, 2021
- Looking At Year Seven On This Cancerversary - Curetoday.com - January 5th, 2021
- JPT Mature Fields and Well Revitalization - Journal of Petroleum Technology - January 5th, 2021
- The 6 big military space stories of 2020 - C4ISRNet - January 5th, 2021
- Comprehensive Report on Magnolia Bark Extract Market 2021 | Trends, Growth Demand, Opportunities & Forecast To 2027 - LionLowdown - January 5th, 2021
- Midlife refit of Scripps' Research Vessel Roger Revelle completed - Research vessel (R/V) Roger Revelle is back at work after a midlife refit... - January 5th, 2021
- 2020: A year of challenge and achievement for Indian nuclear sector - The Siasat Daily - January 5th, 2021
- Equinor stakes NOK 3 billion to improve Statfjord Ost oil recovery - WorldOil - December 28th, 2020
- Antibody study aims to protect those exposed to coronavirus from illness - The Jerusalem Post - December 28th, 2020
- Five Persistent Misconceptions About Modernizing The US ICBM Force - Forbes - December 28th, 2020
- Commercial constellations don't live up to the hype: Euroconsult - SatelliteProME.com - December 14th, 2020
- Global Antioxidant Supplement Market Proceeds To Witness Huge Upswing Over Assessment Period by 2025 - The Courier - December 14th, 2020
- The end of coal? Why investors aren't buying the myth of the industry's 'renaissance' - The Guardian - December 14th, 2020
- Fiore Gold Reports Two Year Mine Life Extension at Its Pan Mine, Nevada - Yahoo Finance - December 10th, 2020
- Crescendo Biologics Expands its Ongoing Collaboration with Takeda - Business Wire - December 10th, 2020
- The 10 Best Creatine Supplements in 2020 - Healthline - December 10th, 2020
- EPZ calls for continued nuclear power in the Netherlands - Nuclear Engineering - December 10th, 2020
- The Global Military Aircraft Modernization and Upgrade and Retrofit Market is expected to grow by $ 2.61 bn during 2020-2024 progressing at a CAGR of... - December 10th, 2020
- Controlled Intelligent Packaging, Preservation and Shelf-Life Extension Market to Witness Widespread Expansion During 2020 to 2026 Cargill Inc.... - December 10th, 2020
- Shelf Life Extension Ingredients Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2028 - Murphy's Hockey Law - December 10th, 2020
- Satellite capacity pricing declines slow, but price pressure expected to increase with new supply entering service in 2023 - Geospatial World - December 6th, 2020
- Team Trump's 2022 budget plan; COVID canks conference; Raytheon, C3.ai team up; and more. - Defense One - December 6th, 2020
- Researchers Think Megastructures Can Help Seed Life Throughout the Galaxy - VICE - December 6th, 2020
- Dehydroepiandrosterone(DHEA) Market 2020-2025 with Growth Factors and Trends with Focusing Key players like BulkSupplements, Natrol, Jarrow Formulas,... - December 6th, 2020
- Shelf Life Extension Ingredients Market Analysis of Key Players, End User, Demand and Consumption By 2028 - The Haitian-Caribbean News Network - December 1st, 2020
- Lubbock weather radar to be down for 2 weeks - Plainview Daily Herald - November 28th, 2020
- Switzerland extends life of CV90s - Jane's - November 28th, 2020
- Impact of COVID-19 on Oral Probiotics Market 2020 Industry Insight, Segment by Key Companies, Countries, Types, Applications and Forecast to 2026 -... - November 28th, 2020
- Incremental Sales to Drive the Cold Plasma Market by 2026 - The Market Feed - November 28th, 2020
- Flight Tests to Show B61-12 Will Work on Air Force's Newest Fighter Jet - I-Connect007 - November 26th, 2020
- An F-35A Dropped An Inert B61-12 Nuclear Bomb During Supersonic Flight For The First Time - The Aviationist - November 26th, 2020
- Flight tests to show B61-12 will work on Air Forces newest fighter jet - Newswise - November 26th, 2020
- Global Bilberry Extract Products Market To Witness Huge Gains Over 2020-2026 - The Courier - November 26th, 2020
- Traditional launch services may not suit the needs of the future Space Force - SpaceNews - November 26th, 2020
- Natural sleeping pills: What are they? - Medical News Today - November 23rd, 2020
- Adagio Therapeutics COVID-19 Antibody Demonstrates Best-in-Class Breadth and Potency Against a Range of Coronaviruses that Pose Human Threat |... - November 23rd, 2020
- Infrastructure and Energy Alternatives, Inc. Extends Service Offering to Wind Customers Through Formation of New Renewable Energy Services Group -... - November 23rd, 2020
- Family fight to make more memories with daughter after pandemic robs them of precious time - North Wales Live - November 23rd, 2020
- NY Power Authority Announces First Milestone of Project to Extend Operating Life of New York's Largest Power Plant - Automation.com - November 18th, 2020
- Cryonics Technology Market Size & Revenue Analysis | Praxair, Cellulis, Cryologics, Cryotherm, KrioRus - The Think Curiouser - November 18th, 2020
- Minot's weather radar will be out of service for approximately one week for scheduled upgrades - Minot Daily News - November 18th, 2020
- Cryonics Technology Market 2020 to Global Forecast 2023 By Key Companies Praxair, Cellulis, Cryologics, Cryotherm, KrioRus, VWR, Thermo Fisher... - November 18th, 2020
- Inside The Navy's Top Aggressor Squadron That Is About To Trade Its Hornets For Super Hornets - The Drive - November 18th, 2020
- Antioxidant Supplement Market Bolstered by Emerging New Advancements, Says QYR | NOW, Vibrant Health, AST R-ALA, GNC - The Think Curiouser - November 18th, 2020
- Why Blade Runner is the best sci-fi movie of all time - Looper - November 18th, 2020
- Column: Just How Old Is 'Old Age' in The Future? - Southern Pines Pilot - November 8th, 2020
- Oral Probiotics Market Outlook, Global Key Players and Covid-19 Impact by 2026 | Oragenics, Life Extension, TheraBreath and Others - TechnoWeekly - November 8th, 2020
- 10 Sci-Fi Movies That Only Make Sense On A Rewatch | ScreenRant - Screen Rant - November 8th, 2020
- Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2020 and Updates Full Year 2020 Guidance - Yahoo... - November 5th, 2020